Brought to you by 
Teva buys Teva Marion interest from Aventis
18 Jan 2002
Executive Summary
Israeli generics company Teva Pharmaceutical will acquire the remaining interest of Teva Marion Partners from Aventis. The 50/50 joint venture was originally set up in 1995 by Hoechst's Marion Merrell Dow division--before the merger of Hoechst and Rhone-Poulenc created Aventis--to market the injectable multiple sclerosis drug Copaxone (glatiramer acetate).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva buys Teva Marion interest from Aventis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice